Screening uptake rates and the clinical and cost effectiveness of screening for gestational diabetes mellitus in primary versus secondary care: study protocol for a randomised controlled trial.
BACKGROUND
The risks associated with gestational diabetes mellitus (GDM) are well recognized, and there is increasing evidence to support treatment of the condition. However, clear guidance on the ideal approach to screening for GDM is lacking. Professional groups continue to debate whether selective screening (based on risk factors) or universal screening is the most appropriate approach. Additionally, there is ongoing debate about what levels of glucose abnormalities during pregnancy respond best to treatment and which maternal and neonatal outcomes benefit most from treatment. Furthermore, the implications of possible screening options on health care costs are not well established. In response to this uncertainty there have been repeated calls for well-designed, randomised trials to determine the efficacy of screening, diagnosis, and management plans for GDM. We describe a randomised controlled trial to investigate screening uptake rates and the clinical and cost effectiveness of screening in primary versus secondary care settings.


METHODS
This will be an unblinded, two-group, parallel randomised controlled trial (RCT). The target population includes 784 women presenting for their first antenatal visit at 12 to 18 weeks gestation at two hospitals in the west of Ireland: Galway University Hospital and Mayo General Hospital. Participants will be offered universal screening for GDM at 24 to 28 weeks gestation in either primary care (n=392) or secondary care (n=392) locations. The primary outcome variable is the uptake rate of screening. Secondary outcomes include indicators of clinical effectiveness of screening at each screening site (primary and secondary) including gestational week at time of screening, time to access antenatal diabetes services for women diagnosed with GDM, and pregnancy and neonatal outcomes for women with GDM. In addition, parallel economic and qualitative evaluations will be conducted. The trial will cover the period from the woman's first hospital antenatal visit at 12 to 18 weeks gestation, until the completion of the pregnancy.


BACKGROUND
Current Controlled Trials: ISRCTN02232125.
School of Medicine, Clinical Sciences Institute, National University of Ireland Galway, Galway, Ireland. angela.odea@nuigalway.ie.
Angela
A
O'Dea
Jennifer J
JJ
Infanti
Paddy
P
Gillespie
Olga
O
Tummon
Samuel
S
Fanous
Liam G
LG
Glynn
Brian E
BE
McGuire
John
J
Newell
Fidelma P
FP
Dunne
D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000378:metabolism; D002985:Clinical Protocols; D003362:Cost-Benefit Analysis; D016640:Diabetes, Gestational / Q000097:blood / Q000175:diagnosis* / Q000191:economics* / Q000628:therapy; D005260:Female; D005865:Gestational Age; D005951:Glucose Tolerance Test / Q000191:economics*; D017048:Health Care Costs; D006801:Humans; D007494:Ireland; D010342:Patient Acceptance of Health Care; D011237:Predictive Value of Tests; D011247:Pregnancy; D011256:Pregnancy Outcome; D011295:Prenatal Care / Q000191:economics*; D011320:Primary Health Care / Q000191:economics*; D012107:Research Design; D063127:Secondary Health Care / Q000191:economics*; D013997:Time Factors
D015415:Biomarkers; D001786:Blood Glucose